News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Sarepta Therapeutics, Inc.
NEWS
JOBS
IN THE PRESS
NEWS
Genetown
Sarepta Jumps Despite DMD Safety Issues in FDA Database
October 3, 2017
·
2 min read
Policy
Sarepta’s Exondys 51 Saga Continues as More Details About FDA’s Criticism Uncovered
August 22, 2017
·
3 min read
Policy
FDA Docs Reveal CDER Chief Skirted Procedures Approving Sarepta’s Controversial Drug Eteplirsen
August 3, 2017
·
1 min read
Deals
New Sarepta CEO’s M&A Experience Sparks Sale Speculation
June 30, 2017
·
3 min read
Business
Sarepta Taps Allergan Alum as New CEO
June 29, 2017
·
2 min read
Policy
Journalist Sues FDA for Documents Related to Sarepta’s DMD Drug
May 26, 2017
·
4 min read
Genetown
Can Sarepta Continue To Live Up To The DMD Hype?
May 8, 2017
·
1 min read
Deals
Sarepta Tests Biotech’s CEO Vacuum Hypothesis
May 2, 2017
·
1 min read
Deals
How Much Rumored Suitors Like Sanofi Would Have To Pay For Sarepta
May 2, 2017
·
1 min read
AWARDS
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Genetown
Sarepta Therapeutics to Announce First Quarter 2021 Financial Results and Recent Corporate Developments on May 5, 2021
April 28, 2021
·
1 min read
Deals
Sarepta Recommends Stockholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
April 26, 2021
·
3 min read
Genetown
Sarepta Therapeutics Announces Fourth Year of Route 79, The Duchenne Scholarship Program
March 23, 2021
·
3 min read
Genetown
Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration
March 18, 2021
·
9 min read
Genetown
Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference
March 15, 2021
·
3 min read
Business
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments
March 1, 2021
·
41 min read
Deals
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 27, 2021
February 26, 2021
·
2 min read
FDA
FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation - Feb 25, 2021
February 25, 2021
·
4 min read
FDA
Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45
February 25, 2021
·
10 min read
Genetown
Sarepta Therapeutics to Present at Upcoming Investor Conferences - Feb 24, 2021
February 24, 2021
·
1 min read
